Cambridge, United States
Beam Therapeutics, founded in 2017, is at the forefront of the biotechnology industry with its cutting-edge use of CRISPR base editing technology. Headquartered in the United States, this innovative company focuses on developing a broad portfolio of genetic medicines that promise lifelong cures for patients suffering from serious diseases.
The company's proprietary base editing approach allows for precise edits to single bases of DNA and RNA without cutting strands, differentiating it as a leader in "precision genetic medicines." This innovative approach combines precision genome targeting with controlled editing outcomes, paving the way for a new class of therapeutic interventions.
In its journey to revolutionize patient care, Beam Therapeutics successfully secured a significant $500.00M Post-Ipo Debt investment from Sixth Street as of 01 February 2026, highlighting investor confidence in its pioneering approach.
Modalis Therapeutics
